{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:45:05Z","timestamp":1760035505580,"version":"build-2065373602"},"reference-count":125,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011033","name":"MCIN\/ AEI \/10.13039\/501100011033","doi-asserted-by":"publisher","award":["PID2019-105128RB-I0","PID2022-136799OB-I00","B31_20R","PI-PRD\/2021-002","FPU17\/02586"],"award-info":[{"award-number":["PID2019-105128RB-I0","PID2022-136799OB-I00","B31_20R","PI-PRD\/2021-002","FPU17\/02586"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010067","name":"Gobierno de Arag\u00f3n","doi-asserted-by":"publisher","award":["PID2019-105128RB-I0","PID2022-136799OB-I00","B31_20R","PI-PRD\/2021-002","FPU17\/02586"],"award-info":[{"award-number":["PID2019-105128RB-I0","PID2022-136799OB-I00","B31_20R","PI-PRD\/2021-002","FPU17\/02586"]}],"id":[{"id":"10.13039\/501100010067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007041","name":"University of Zaragoza","doi-asserted-by":"publisher","award":["PID2019-105128RB-I0","PID2022-136799OB-I00","B31_20R","PI-PRD\/2021-002","FPU17\/02586"],"award-info":[{"award-number":["PID2019-105128RB-I0","PID2022-136799OB-I00","B31_20R","PI-PRD\/2021-002","FPU17\/02586"]}],"id":[{"id":"10.13039\/501100007041","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Ministry of Universities","award":["PID2019-105128RB-I0","PID2022-136799OB-I00","B31_20R","PI-PRD\/2021-002","FPU17\/02586"],"award-info":[{"award-number":["PID2019-105128RB-I0","PID2022-136799OB-I00","B31_20R","PI-PRD\/2021-002","FPU17\/02586"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The treatment landscape for multiple myeloma (MM) has significantly evolved in recent decades with novel therapies like proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. However, MM remains incurable, necessitating new pharmacological strategies. Mitotic kinases, such as Aurora proteins, have emerged as potential targets. Selective inhibitors of Aurora A and B,- alisertib (MLN8237) and barasertib (AZD1152), respectively, have shown anti-myeloma activity in preclinical studies, with alisertib demonstrating modest efficacy in early clinical trials. Methods and Results: This study investigated the mechanisms of action of alisertib and barasertib and their combination with antitumor agents in a panel of five MM cells lines. Both drugs induced cell cycle arrest phase and abnormal nuclear morphologies. Alisertib caused prolonged mitotic arrest, whereas barasertib induced transient arrest, both resulting in the activation of mitotic catastrophe. These findings revealed three potential outcomes: cell death, senescence, or polyploidy. High mitochondrial reactive oxygen species (mROS) were identified as possible drivers of cell death. Caspase inhibition reduced caspase-3 activation but did not prevent cell death. Interestingly, alisertib at low doses remained toxic to Bax\/BakDKO cells, although mitochondrial potential disruption and cytochrome c release were observed. Sequential combinations of high-dose Aurora kinase inhibitors with BH3-mimetics, and in specific cases with panobinostat, showed a synergistic effect. Conversely, the simultaneous combination of alisertib and barasertib showed mostly antagonistic effects. Conclusions: Alisertib and barasertib emerge as potential in vitro candidates against MM, although further studies are needed to validate their efficacy and to find the best combinations with other molecules.<\/jats:p>","DOI":"10.3390\/cancers17142290","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:38:27Z","timestamp":1752140307000},"page":"2290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alisertib and Barasertib Induce Cell Cycle Arrest and Mitochondria-Related Cell Death in Multiple Myeloma with Enhanced Efficacy Through Sequential Combination with BH3-Mimetics and Panobinostat"],"prefix":"10.3390","volume":"17","author":[{"given":"Andrea","family":"Benedi","sequence":"first","affiliation":[{"name":"Apoptosis, Immunity & Cancer Group, Instituto de Investigaci\u00f3n Sanitaria-Arag\u00f3n, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Beltr\u00e1n-Visiedo","sequence":"additional","affiliation":[{"name":"Apoptosis, Immunity & Cancer Group, Instituto de Investigaci\u00f3n Sanitaria-Arag\u00f3n, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0381-3292","authenticated-orcid":false,"given":"Nelia","family":"Jim\u00e9nez-Aldu\u00e1n","sequence":"additional","affiliation":[{"name":"Apoptosis, Immunity & Cancer Group, Instituto de Investigaci\u00f3n Sanitaria-Arag\u00f3n, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Serrano-Del Valle","sequence":"additional","affiliation":[{"name":"Apoptosis, Immunity & Cancer Group, Instituto de Investigaci\u00f3n Sanitaria-Arag\u00f3n, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-8394","authenticated-orcid":false,"given":"Alberto","family":"Anel","sequence":"additional","affiliation":[{"name":"Apoptosis, Immunity & Cancer Group, Instituto de Investigaci\u00f3n Sanitaria-Arag\u00f3n, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2156-8378","authenticated-orcid":false,"given":"Javier","family":"Naval","sequence":"additional","affiliation":[{"name":"Apoptosis, Immunity & Cancer Group, Instituto de Investigaci\u00f3n Sanitaria-Arag\u00f3n, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2315-9079","authenticated-orcid":false,"given":"Isabel","family":"Marzo","sequence":"additional","affiliation":[{"name":"Apoptosis, Immunity & Cancer Group, Instituto de Investigaci\u00f3n Sanitaria-Arag\u00f3n, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10585-007-9108-4","article-title":"Extravasation and homing mechanisms in multiple myeloma","volume":"25","author":"Vanderkerken","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pinto, V., Bergantim, R., Caires, H.R., Seca, H., Guimar\u00e3es, J.E., and Vasconcelos, M.H. (2020). Multiple myeloma: Available therapies and causes of drug resistance. Cancers, 12.","DOI":"10.3390\/cancers12020407"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41375-018-0362-z","article-title":"The future of myeloma precision medicine: Integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies","volume":"33","author":"Harding","year":"2019","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: A comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","article-title":"The cellular geography of aurora kinases","volume":"4","author":"Carmena","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood-2006-07-037671","article-title":"Targeting aurora kinases as therapy in multiple myeloma","volume":"109","author":"Shi","year":"2007","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrm3474","article-title":"The chromosomal passenger complex (CPC): From easy rider to the godfather of mitosis","volume":"13","author":"Carmena","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/humrep\/der111","article-title":"A role for Aurora C in the chromosomal passenger complex during human preimplantation embryo development","volume":"26","author":"Jahr","year":"2011","journal-title":"Human. Reprod."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.gde.2006.12.008","article-title":"Cell cycle kinases in cancer","volume":"17","author":"Malumbres","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood-2007-06-097774","article-title":"The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition","volume":"111","author":"Chng","year":"2008","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/labinvest.2009.106","article-title":"Analysis of Aurora B kinase in non-Hodgkin lymphoma","volume":"89","author":"Ikezoe","year":"2009","journal-title":"Lab. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-07-0067","article-title":"A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia","volume":"6","author":"Ikezoe","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","first-page":"991","article-title":"Overexpression of Oncogenic STK15\/BTAK\/Aurora A Kinase in Human Pancreatic Cancer","volume":"9","author":"Li","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.onc.1201065","article-title":"A putative serine\/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines","volume":"14","author":"Sen","year":"1997","journal-title":"Oncogene"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.leukres.2010.07.034","article-title":"High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia","volume":"35","author":"Falcao","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","article-title":"Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma","volume":"113","author":"Hose","year":"2009","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4161\/cc.11.4.19323","article-title":"The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent","volume":"11","author":"Nair","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","article-title":"Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of Aurora A kinase using novel in vivo pharmacodynamic assays","volume":"17","author":"Manfredi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1107\/S2053230X14002118","article-title":"Structure of Aurora B-INCENP in complex with barasertib reveals a potential transinhibitory mechanism","volume":"70","author":"Sessa","year":"2014","journal-title":"Acta Crystallogr. F Struct. Biol. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.15563","article-title":"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia","volume":"185","author":"Dohner","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and Cytogenetics of Multiple Myeloma","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2016.325","article-title":"Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma","volume":"31","author":"Qin","year":"2017","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3324\/haematol.2018.208280","article-title":"Functional interplay between NF-kappaB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma","volume":"104","author":"Mazzera","year":"2019","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2008-12-194290","article-title":"Aurora kinase A is a target of Wnt\/beta-catenin involved in multiple myeloma disease progression","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/1440-1681.12571","article-title":"An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor","volume":"43","author":"Durlacher","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_27","first-page":"845","article-title":"Alisertib induces G2\/M arrest, apoptosis, and autophagy via PI3K\/Akt\/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cells","volume":"9","author":"Liu","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Niu, H., Manfredi, M., and Ecsedy, J.A. (2015). Scientific rationale supporting the clinical development strategy for the investigational Aurora A kinase inhibitor alisertib in cancer. Front. Oncol., 5.","DOI":"10.3389\/fonc.2015.00189"},{"key":"ref_29","first-page":"1027","article-title":"The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells","volume":"2015","author":"Li","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ren, B.-J., Zhou, Z.-W., Zhu, D.-J., Ju, Y.-L., Wu, J.-H., Ouyang, M.-Z., Chen, X.-W., and Zhou, S.-F. (2016). Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010041"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Borah, N.A., and Reddy, M.M. (2021). Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer. Molecules, 26.","DOI":"10.3390\/molecules26071981"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bavetsias, V., and Linardopoulos, S. (2015). Aurora Kinase Inhibitors: Current Status and Outlook. Front. Oncol., 5.","DOI":"10.3389\/fonc.2015.00278"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"136178","DOI":"10.1016\/j.molstruc.2023.136178","article-title":"Selective targeting of Aurora kinase B over A: Uncovering the structural basis for inhibitor specificity through molecular dynamics simulations","volume":"1292","author":"Zhao","year":"2023","journal-title":"J. Mol. Struct."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/cas.12164","article-title":"Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells","volume":"104","author":"Yamauchi","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3892\/mmr.2016.5249","article-title":"Alisertib induces apoptosis and autophagy through targeting the AKT\/mTOR\/AMPK\/p38 pathway in leukemic cells","volume":"14","author":"Fu","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-013-0050-9","article-title":"Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed\/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"32","author":"Kelly","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_37","first-page":"1627","article-title":"The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2\/M arrest, apoptosis, and autophagy via p38 MAPK and Akt\/mTOR signaling pathways in human breast cancer cells","volume":"2015","author":"Li","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_38","first-page":"575","article-title":"Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K\/Akt\/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells","volume":"9","author":"Wang","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gupta, D., Kumar, M., Saifi, S., Rawat, S., Ethayathulla, A.S., and Kaur, P. (2024). A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics. Int. J. Biol. Macromol., 265.","DOI":"10.1016\/j.ijbiomac.2024.130913"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/1535-7163.MCT-17-0223","article-title":"Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer","volume":"16","author":"Montero","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100326","DOI":"10.18632\/oncotarget.22222","article-title":"Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: A novel therapeutic strategy","volume":"8","author":"Islam","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/med.21994","article-title":"Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy","volume":"44","author":"Lakkaniga","year":"2024","journal-title":"Med. Res. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1158\/1078-0432.CCR-18-0440","article-title":"Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck","volume":"25","author":"Lee","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mahadevan, D., Morales, C., Cooke, L.S., Manziello, A., Mount, D.W., Persky, D.O., Fisher, R.I., Miller, T.P., and Qi, W. (2014). Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095184"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pharmthera.2017.02.007","article-title":"Anti-mitotic agents: Are they emerging molecules for cancer treatment?","volume":"173","author":"Penna","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Maiga","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: Lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/ml5001867","article-title":"Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity","volume":"5","author":"Tao","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"279ra240","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/jphp.13240","article-title":"Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma","volume":"72","author":"Wong","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.3324\/haematol.2018.212308","article-title":"Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma","volume":"105","author":"Corchete","year":"2020","journal-title":"Haematologica"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","article-title":"A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma","volume":"115","author":"Gorgun","year":"2010","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/10428190701824544","article-title":"Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells","volume":"49","author":"Evans","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/1878-0261.13522","article-title":"Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-X(L) in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients","volume":"17","author":"Diez","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-5793(95)01236-1","article-title":"mtDNA-depleted U937 cells are sensitive to TNF and Fas-mediated cytotoxicity","volume":"376","author":"Gamen","year":"1995","journal-title":"FEBS Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nprot.2009.143","article-title":"Expression, purification and use of recombinant annexin V for the detection of apoptotic cells","volume":"4","author":"Logue","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3324\/haematol.2014.117531","article-title":"Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide","volume":"100","author":"Nijhof","year":"2015","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15384101.2018.1559557","article-title":"Mitotic slippage: An old tale with a new twist","volume":"18","author":"Sinha","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrm3115","article-title":"Mitotic catastrophe: A mechanism for avoiding genomic instability","volume":"12","author":"Vitale","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/B978-0-12-407695-2.00007-X","article-title":"Role of Cyclin B1 Levels in DNA Damage and DNA Damage-Induced Senescence","volume":"305","author":"Nakayama","year":"2013","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: Outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.cdd.4400629","article-title":"Distinct stages of cytochrome c release from mitochondria: Evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis","volume":"7","author":"Chen","year":"2000","journal-title":"Cell Death Differ."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bcp.2010.02.010","article-title":"Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells","volume":"79","author":"Yuste","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2021.279517","article-title":"Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition","volume":"107","author":"Cuenca","year":"2022","journal-title":"Haematologica"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: Pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.celrep.2017.09.085","article-title":"High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer","volume":"21","author":"Wang","year":"2017","journal-title":"Cell Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1182\/blood-2022-159806","article-title":"Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients","volume":"140","author":"Pan","year":"2022","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","article-title":"Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma","volume":"21","author":"Zullo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/cam4.289","article-title":"Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer","volume":"3","author":"Paller","year":"2014","journal-title":"Cancer Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"90501","DOI":"10.18632\/oncotarget.18765","article-title":"The therapeutic potential of cell cycle targeting in multiple myeloma","volume":"8","author":"Maes","year":"2017","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2015.1091927","article-title":"A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191","volume":"57","author":"Hay","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjh.13765","article-title":"A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma","volume":"174","author":"Rosenthal","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2007.06913.x","article-title":"The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma","volume":"140","author":"Evans","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.leukres.2012.10.017","article-title":"Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment","volume":"37","author":"Qi","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_82","first-page":"516","article-title":"Inhibition of Polo-Like Kinase 1 Induces Cell Cycle Arrest and Sensitizes Glioblastoma Cells to Ionizing Radiation","volume":"28","author":"Pezuk","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_83","first-page":"335","article-title":"Cyclin B1 and CDK1: Nuclear localization and upstream regulators","volume":"5","author":"Porter","year":"2003","journal-title":"Progress. Cell Cycle Res."},{"key":"ref_84","first-page":"425","article-title":"Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells","volume":"2015","author":"Ding","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1535-7163.MCT-18-0529","article-title":"Aurora A\u2013Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy","volume":"18","author":"Du","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"29887","DOI":"10.1074\/jbc.M112.371682","article-title":"Aurora B Is Regulated by the Mitogen-activated Protein Kinase\/Extracellular Signal-regulated Kinase (MAPK\/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells","volume":"287","author":"Bonet","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/emmm.201201378","article-title":"Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-\u03baB impairs this drug-induced senescence","volume":"5","author":"Liu","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1002\/cam4.1771","article-title":"An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression","volume":"7","author":"Ryu","year":"2018","journal-title":"Cancer Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"51786","DOI":"10.1074\/jbc.M306275200","article-title":"Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells","volume":"278","author":"Marumoto","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1078-0432.CCR-12-2383","article-title":"The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo","volume":"19","author":"Zhou","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.2010.033456","article-title":"A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines","volume":"96","author":"Moreaux","year":"2011","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2009.08.011","article-title":"Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways","volume":"79","author":"Li","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2016.02.026","article-title":"BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation","volume":"165","author":"Llambi","year":"2016","journal-title":"Cell"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.4161\/cc.25914","article-title":"Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors","volume":"12","author":"Ierano","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-023-04503-0","article-title":"The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo","volume":"91","author":"Sak","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1038\/s41467-021-25501-x","article-title":"Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma","volume":"12","author":"Nguyen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"12634","DOI":"10.1073\/pnas.0913615107","article-title":"Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization","volume":"107","author":"Shah","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"16623","DOI":"10.1074\/jbc.M611060200","article-title":"A Bax\/Bak-independent Mechanism of Cytochrome c Release","volume":"282","author":"Mizuta","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.1074\/jbc.M707687200","article-title":"Chelerythrine Induces Apoptosis through a Bax\/Bak-independent Mitochondrial Mechanism","volume":"283","author":"Wan","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Nguyen, C., and Pandey, S. (2019). Exploiting Mitochondrial Vulnerabilities to Trigger Apoptosis Selectively in Cancer Cells. Cancers, 11.","DOI":"10.3390\/cancers11070916"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/bjc.2012.527","article-title":"PDK1 inhibition is a novel therapeutic target in multiple myeloma","volume":"108","author":"Fujiwara","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/bjc.2013.120","article-title":"Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib","volume":"108","author":"Sanchez","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"35247","DOI":"10.18632\/oncotarget.6208","article-title":"Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma","volume":"6","author":"Bogen","year":"2015","journal-title":"Oncotarget"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000258705","article-title":"ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropancreatic Neuroendocrine Tumor Cell Lines","volume":"91","author":"Georgieva","year":"2010","journal-title":"Neuroendocrinology"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Li, J., Chen, C.-H., O\u2019Neill, K.L., Fousek-Schuller, V.J., Black, A.R., Black, J.D., Zhang, J., and Luo, X. (2023). Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins. J. Biol. Chem., 299.","DOI":"10.1016\/j.jbc.2023.102875"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41418-020-00604-y","article-title":"Phosphorylation by Aurora B kinase regulates caspase-2 activity and function","volume":"28","author":"Lim","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"17599","DOI":"10.1074\/jbc.M602641200","article-title":"Caspase-2 Triggers Bax-Bak-dependent and -independent Cell Death in Colon Cancer Cells Treated with Resveratrol","volume":"281","author":"Mohan","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.cdd.4402044","article-title":"Broad-spectrum caspase inhibitors: From myth to reality?","volume":"14","author":"Chauvier","year":"2007","journal-title":"Cell Death Differ"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.taap.2011.11.021","article-title":"Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold","volume":"258","author":"Vela","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_111","first-page":"1555","article-title":"Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK\/PI3K\/Akt\/mTOR signaling pathway","volume":"2015","author":"Niu","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Wang, L.-X., Wang, J.-D., Chen, J.-J., Long, B., Liu, L.-L., Tu, X.-X., Luo, Y., Hu, Y., Lin, D.-J., and Lu, G. (2016). Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation. Sci. Rep., 6.","DOI":"10.1038\/srep35533"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/1878-0261.13025","article-title":"Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases","volume":"16","author":"Jane","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1158\/0008-5472.CAN-05-1162","article-title":"Resistance to Paclitaxel Is Proportional to Cellular Total Antioxidant Capacity","volume":"65","author":"Ramanathan","year":"2005","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Mailloux, R.J. (2020). An Update on Mitochondrial Reactive Oxygen Species Production. Antioxidants, 9.","DOI":"10.3390\/antiox9060472"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"955","DOI":"10.18632\/aging.101202","article-title":"New agents that target senescent cells: The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463","volume":"9","author":"Zhu","year":"2017","journal-title":"Aging"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41419-020-02887-y","article-title":"Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance","volume":"11","author":"Alcon","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-019-13689-y","article-title":"STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment","volume":"11","author":"Lohard","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Manzano-Mu\u00f1oz, A., Alcon, C., Men\u00e9ndez, P., Ram\u00edrez, M., Seyfried, F., Debatin, K.-M., Meyer, L.H., Samitier, J., and Montero, J. (2021). MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.695225"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Hontecillas-Prieto, L., Flores-Campos, R., Silver, A., de \u00c1lava, E., Hajji, N., and Garc\u00eda-Dom\u00ednguez, D.J. (2020). Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.578011"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood.V108.11.847.847","article-title":"Aurora Kinases as Therapeutic Targets in Multiple Myeloma","volume":"108","author":"Reiman","year":"2006","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1535-7163.MCT-07-0444","article-title":"PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer","volume":"6","author":"Carpinelli","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/ijc.26324","article-title":"AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas","volume":"130","author":"Qi","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.4161\/cc.6.22.4940","article-title":"VX-680 Inhibits Aurora A and Aurora B Kinase Activity in Human Cells","volume":"6","author":"Tyler","year":"2007","journal-title":"Cell Cycle"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/14\/2290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:07:32Z","timestamp":1760033252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/14\/2290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":125,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17142290"],"URL":"https:\/\/doi.org\/10.3390\/cancers17142290","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,7,9]]}}}